Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

FDA knocks-back Otsuka's digital pill plans

Wants more data on its combination of Abilify and Proteus sensor and pill

Proteus Digital Health digital medicine

Otsuka's plans to combine its antipsychotic drug Abilify with Proteus' digital pill to measure adherence have suffered a setback in the US after the FDA declined to approve the drug/device tie-up.

The regulator instead issued a Complete Response Letter for the 'digital medicine' requesting additional information, including data on the product's performance under the conditions in which it is likely to be used.

The FDA also wants 'human factors investigations', to evaluate any use-related risks with the Otsuka/Proteus device and to confirm patients will be able to use it safely and effectively.

Otsuka had submitted the device for approval to measure medication adherence to Abilify (aripiprazole) in patients with schizophrenia, as an acute treatment of manic and mixed episodes associated with bipolar I disorder and as an adjunctive treatment for major depressive disorder (MDD).

Robert McQuade, executive vice president and chief strategy officer, Otsuka Pharmaceutical Development & Commercialisation, said: “While we are disappointed in the FDA's decision not to approve this digital medicine at this time, both Otsuka and Proteus are committed to working with the FDA to address its questions and provide the additional data that has been requested.”

Proteus' digital medicine has, by itself, already been approved by the FDA. The technology uses a tiny sensor that is activated in the stomach and communicates information about how an individual is taking their medication and how their body is responding to therapy.

This information is communicated via a patch the patient wears to enable more effective monitoring of patients and to help them take charge of their health.

6th May 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...
2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....

Infographics